Virtus Biotech ETF
BBP
17 hedge funds and large institutions have $10.9M invested in Virtus Biotech ETF in 2018 Q3 according to their latest regulatory filings, with 1 funds opening new positions, 7 increasing their positions, 4 reducing their positions, and 1 closing their positions.
444% more capital inflows, than outflows
Capital inflows: $930K | Capital outflows: $171K
75% more repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 4
2.26% more ownership
Funds ownership: 29.75% → 32.01% (+2.3%)
0% more funds holding
Funds holding: 17 → 17 (0)
0% more first-time investments, than exits
New positions opened: 1 | Existing positions closed: 1
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Jane Street
New York
|
+$347K |
| 2 |
Morgan Stanley
New York
|
+$230K |
| 3 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
+$190K |
| 4 |
Smart Money Group
Eastland,
Texas
|
+$72K |
| 5 |
UBS Group
Zurich,
Switzerland
|
+$34.4K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Federation des caisses Desjardins du Quebec
Levis,
Quebec, Canada
|
-$87.7K |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$66.9K |
| 3 |
Financial Advocates Investment Management
Olympia,
Washington
|
-$11.6K |
| 4 |
JP Morgan Chase
New York
|
-$3.89K |
| 5 |
Stifel Financial
St. Louis,
Missouri
|
-$715 |
BBP Hedge Fund Activity: Q3 2018 in Review
17 of the 4,392 institutional investors tracked by Wall St. Rank reported a position in Virtus Biotech ETF (BBP) for Q3 2018, worth a combined $10.9M — up 12% from $9.8M a quarter earlier.
Fund positioning in BBP was balanced in Q3 2018: 1 fund opened new positions, 1 closed out, 7 added to existing stakes and 4 trimmed.
The largest buyer was Jane Street, opening a new position worth an estimated $347K. The largest seller was Federation des caisses Desjardins du Quebec, exiting entirely with an estimated $87.7K sold.
- 17 institutional investors held Virtus Biotech ETF (BBP) as of Q3 2018, unchanged from Q2 2018.
- Funds reported $10.9M of Virtus Biotech ETF stock for Q3 2018, up 12% quarter-over-quarter.
- 1 fund opened new Virtus Biotech ETF positions in Q3 2018 and 1 closed out, a net change of 0 holders.
- The largest Virtus Biotech ETF buyer in Q3 2018 was Jane Street, an estimated $347K added.
- The largest Virtus Biotech ETF seller in Q3 2018 was Federation des caisses Desjardins du Quebec, an estimated $87.7K sold.
Based on aggregated 13F filings for Q3 2018.